SecBot SecBot
6-K ·Filed Sep 8, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonweeks Processed2mo ago SEC0001434265-26-000116
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the EGM vote outcome on October 7, 2026, for any signal of shareholder dissent, but this is a routine governance matter with no expected impact on operations or stock price.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$33.53
T+0 close · Sep 8, 2026 · via day close
Latest settled
+12.73%
T+20 · $37.80 · next T+60 in 15d
Vs SPY
+10.77%
α at T+20
Latest observation
+61.11%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $33.53entry
  2. T+1 · 2mo ago −1.46%α −1.00% · $33.04
  3. T+5 · 2mo ago −2.62%α −1.96% · $32.65
  4. T+20 · 6w ago +12.73%α +10.77% · $37.80
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab A/S filed a 6-K convening an Extraordinary General Meeting on October 7, 2026, to seek shareholder approval of the Board of Directors' remuneration for 2026, which remains unchanged from 2024 and 2025. The proposal was withdrawn at the March 2026 AGM, prompting extensive shareholder outreach; the Board recalibrated the compensation peer group to an equal mix of U.S. and European companies but retained current fee levels and the service-based RSU structure. This is a routine governance matter with no material financial impact on the company's operations or fundamentals.

Key Facts

  • Genmab is holding an EGM on October 7, 2026, to vote on Board remuneration for 2026.
  • The remuneration proposal was withdrawn at the March 19, 2026 AGM, leading to shareholder outreach covering over 60% of share capital.
  • The Board recalibrated the peer group from 13 U.S. and 7 European companies to an equal mix of 10 U.S. and 10 European companies.
  • Annual base fees and share-based RSU remuneration remain unchanged from 2024 and 2025.
  • The Board decided not to adjust remuneration levels despite considering reductions based on shareholder feedback.

Financial Impact

No material financial impact; director remuneration is a routine governance expense.

Risk Factors

  • Potential shareholder dissent if the unchanged remuneration fails to gain majority support at the EGM.
  • Continued governance scrutiny from proxy advisors and institutional investors may lead to future adjustments.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000116
Document: gmab_20260908xex99d1.htm0001434265-26-000116
Document: gmab_20260908xex99d3.htm0001434265-26-000116
Document: gmab_20260908x6k.htm0001434265-26-000116
Document: 0001434265-26-000116-index-headers.html0001434265-26-000116
Document: 0001434265-26-000116-index.html0001434265-26-000116
Document: 0001434265-26-000116.txt0001434265-26-000116

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026